<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04157933</url>
  </required_header>
  <id_info>
    <org_study_id>AMDC-009-102</org_study_id>
    <nct_id>NCT04157933</nct_id>
  </id_info>
  <brief_title>Staccato Apomorphine Multi-dose PK and PD in Patients With Parkinson's Disease</brief_title>
  <official_title>A Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Profile of AZ-009 in Subjects With Established Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexza Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexza Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted in subjects with established Parkinson's disease in 2 parts.
      Part A will examine the tolerability, safety, and pharmacokinetics of AZ-009 dose escalation
      ; and Part B will assess the tolerability, safety, pharmacokinetics, and pharmacodynamics of
      AZ-009 compared with placebo in a crossover design
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be conducted in subjects with established Parkinson's disease in 2 parts.

      Part A will examine the tolerability, safety, and pharmacokinetics of daily doses of AZ-009
      for 5 days followed by 3 doses on each of days 6 and 7 in dose escalation through 3 cohorts

      Part B will assess the tolerability, safety, pharmacokinetics, and pharmacodynamics of AZ-009
      compared with placebo in subjects with established Parkinson's disease experiencing regular
      OFF episodes
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">October 16, 2019</start_date>
  <completion_date type="Anticipated">March 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study will be conducted in subjects with established Parkinson's disease in 2 parts. Part A will examine the tolerability, safety, and pharmacokinetics of AZ-009 dose escalation ; and Part B will assess the tolerability, safety, pharmacokinetics, and pharmacodynamics of AZ-009 compared with placebo in a crossover design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A - Dose Proportionality of multi-dose inhaled apomorphine by Power Analysis of AUC</measure>
    <time_frame>6 days</time_frame>
    <description>Dose proportionality of inhaled Staccato apomorphine AUC across all 3 doses during Days 1-5 and multiple daily dosing (all 3 doses q 2 hr per day) on Day 6 using a power model [regression of log(AUC) versus log(dose)] in subjects with established Parkinson's disease</description>
  </primary_outcome>
  <primary_outcome>
    <measure>B1 - Effect on MDS-UPDRS in Parkinson's disease OFF periods</measure>
    <time_frame>2 days</time_frame>
    <description>Explore in a crossover design on consecutive days the pharmacodynamics of AZ-009 compared with placebo on the Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III in subjects with established Parkinson's disease experiencing regular OFF episodes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>B2 - Effect on Physician Disease State Assessment in Parkinson's disease OFF periods</measure>
    <time_frame>2 days</time_frame>
    <description>Explore in a crossover design on consecutive days the pharmacodynamics of AZ-009 compared with placebo on the Physician Disease State Assessment in subjects with established Parkinson's disease experiencing regular OFF episodes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>B3 - Effect on Patient Assessment of ON/OFF in Parkinson's disease OFF periods</measure>
    <time_frame>2 days</time_frame>
    <description>Explore in a crossover design on consecutive days the pharmacodynamics of AZ-009 compared with placebo on Patient Assessment of ON/OFF in subjects with established Parkinson's disease experiencing regular OFF episodes.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>A-1a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A, Arm 1 (active), Dose 1 (009-A1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A-2a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A, Arm 2 (active), Dose 2 (009-A2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A-3a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A, Arm 3 (active), Dose 3 (009-A3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A-0p</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part A, placebo comparator in all 3 arms, placebo dose (009-A0)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B-1 (009-B3 -&gt; 009-B0)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Crossover (active to placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B-1 (009-B0 -&gt; 009-B3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Crossover (placebo to active)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>009-A1</intervention_name>
    <description>Inhaled apomorphine via Staccato aerosol, Dose 1 (low dose) each day for first 5 days, then 3 doses Dose 1 (low dose) q 2 hr on Day 6</description>
    <arm_group_label>A-1a</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>009-A2</intervention_name>
    <description>Inhaled apomorphine via Staccato aerosol, Dose 2 (middle dose) each day for first 5 days, then 3 doses Dose 2 (middle dose) q 2 hr on Day 6</description>
    <arm_group_label>A-2a</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>009-A3</intervention_name>
    <description>Inhaled apomorphine via Staccato aerosol, Dose 3 (high dose) each day for first 5 days, then 3 doses Dose 3 (high dose) q 2 hr on Day 6</description>
    <arm_group_label>A-3a</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>009-A0</intervention_name>
    <description>Inhaled placebo via Staccato aerosol, Dose 0 (placebo) each day for first 5 days, then 3 doses Dose 0 (placebo) q 2 hr on Day 6</description>
    <arm_group_label>A-0p</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>009-B1 (active --&gt; placebo) crossover</intervention_name>
    <description>Up to 2 doses (Dose 3) ; minimum of 2 hrs between doses, on Day 1, followed by Up to 2 doses (placebo) ; minimum of 2 hrs between doses, on Day 2</description>
    <arm_group_label>B-1 (009-B3 -&gt; 009-B0)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>009-B2 (placebo --&gt; active) crossover</intervention_name>
    <description>Up to 2 doses (placebo) ; minimum of 2 hrs between doses, on Day 1, followed by Up to 2 doses (Dose 3) ; minimum of 2 hrs between doses, on Day 2</description>
    <arm_group_label>B-1 (009-B0 -&gt; 009-B3)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult males and females between 30 and 85 years of age, inclusive at the time
             of signing the informed consent document with a clinical diagnosis of Parkinson's
             Disease

          -  Body weight â‰¥ 50 kg and BMI within the range of 18 to 32 kg/m2.

          -  Willing and able to be confined at the clinical research center for the study period
             and adhere to overall study visit schedule, procedures and other protocol
             requirements.

          -  Understand and voluntarily sign an informed consent document prior to any study
             related assessments/procedures being conducted.

        Exclusion Criteria:

          -  Any significant medical condition, psychiatric illness or history of depression that
             could, in the investigator's opinion, compromise the subject's safety or interfere
             with the completion of this protocol.

          -  History of clinically significant central nervous system, cardiac, pulmonary,
             metabolic, renal, hepatic, or gastrointestinal conditions including gastric bypass or
             other weight loss
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geert J Groeneveld, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Human Drug Research (The Netherlands)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre for Human Drug Research</name>
      <address>
        <city>Leiden</city>
        <zip>2333</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>November 1, 2019</study_first_submitted>
  <study_first_submitted_qc>November 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2019</study_first_posted>
  <last_update_submitted>March 1, 2020</last_update_submitted>
  <last_update_submitted_qc>March 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

